ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,303.27
      0.12%
      US Tech 100
      18,064.00
      -0.08%
      Dow Jones
      40,003.59
      0.34%
      Brent Oil
      83.76
      0.67%
      Bitcoin
      66,886.16
      2.52%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Acumen Pharmaceuticals Inc (ABOS)

      7. Acumen Pharmaceuticals Inc (ABOS) News

      ABOS

      Acumen Pharmaceuticals (ABOS)

      Acumen Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ABOS
      DateTimeSourceHeadlineSymbolCompany
      3:00PMiHub NewswireFeaturedMusic Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements
      05/14/20244:47PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABOSAcumen Pharmaceuticals Inc
      05/14/20247:35AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABOSAcumen Pharmaceuticals Inc
      05/14/20247:00AMGlobeNewswire Inc.Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:ABOSAcumen Pharmaceuticals Inc
      05/13/20244:00PMGlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
      05/08/20245:47PMGlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
      05/08/20248:00AMGlobeNewswire Inc.Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s DiseaseNASDAQ:ABOSAcumen Pharmaceuticals Inc
      05/07/20244:00PMGlobeNewswire Inc.Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
      04/16/20248:00AMGlobeNewswire Inc.Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
      04/04/20248:00AMGlobeNewswire Inc.Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s DiseaseNASDAQ:ABOSAcumen Pharmaceuticals Inc
      03/26/20247:00AMGlobeNewswire Inc.Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business HighlightsNASDAQ:ABOSAcumen Pharmaceuticals Inc
      03/21/20248:00AMGlobeNewswire Inc.Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
      03/19/20244:00PMGlobeNewswire Inc.Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
      03/12/20244:00PMGlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS DaysNASDAQ:ABOSAcumen Pharmaceuticals Inc
      03/08/20248:50AMGlobeNewswire Inc.Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
      02/21/20248:00AMGlobeNewswire Inc.Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
      02/14/20248:32AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABOSAcumen Pharmaceuticals Inc
      02/01/20245:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
      02/01/20245:01PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
      02/01/20247:16AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABOSAcumen Pharmaceuticals Inc
      02/01/20247:00AMGlobeNewswire Inc.Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development OfficerNASDAQ:ABOSAcumen Pharmaceuticals Inc
      01/19/20247:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
      01/19/20247:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
      01/19/20247:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
      01/19/20247:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
      01/19/20247:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
      01/19/20244:36PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
      01/19/20244:35PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
      01/18/20244:29PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
      01/18/20244:28PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:ABOS